Product Description: Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research[1].
Applications: Neuroscience-Neuromodulation
Formula: N/A
References: [1]Yvette N Lamb. Galcanezumab: First Global Approval. Drugs. 2018 Nov;78(16):1769-1775.